90TiP FRAIL-IMMUNE: A multicenter, prospective, single arm phase II of the combination of durvalumab with carboplatin and paclitaxel as first-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck not eligible to standard chemotherapy (GORTEC 2018-03)

123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial

Annals of Oncology ◽

10.1016/j.annonc.2021.10.142 ◽

2021 ◽

Vol 32 ◽

pp. S1432

Author(s):

D.A. Colevas ◽

K. Misiukiewicz ◽

A.T. Pearson ◽

J. Fayette ◽

J.R. Bauman ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Faculty Opinions recommendation of Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13355993.791652823 ◽

2012 ◽

Author(s):

Marco Merlano

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Faculty Opinions recommendation of Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13355993.14726100 ◽

2011 ◽

Author(s):

Jan Vermorken

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Faculty Opinions recommendation of Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13355993.14726135 ◽

2011 ◽

Author(s):

Pol Specenier

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck

Annals of Oncology ◽

10.1093/annonc/mdr367 ◽

2012 ◽

Vol 23 (4) ◽

pp. 1016-1022 ◽

Cited By ~ 102

Author(s):

R. Hitt ◽

A. Irigoyen ◽

H. Cortes-Funes ◽

J.J. Grau ◽

J.A. García-Sáenz ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Observational study of the cetuximab relative dose intensity (RDI) in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Data on the maintenance and every two weeks use (DIRECT study)

Annals of Oncology ◽

10.1093/annonc/mdw376.19 ◽

2016 ◽

Vol 27 ◽

pp. vi334 ◽

Cited By ~ 2

Author(s):

J. Guigay ◽

E. Chamorey ◽

P. Céruse ◽

F. Mornex ◽

M. Degardin ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Observational Study ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Dose Intensity ◽

Line Treatment ◽

First Line ◽

972TiP Phase II study of intratumoral MK-1454 plus pembrolizumab compared with pembrolizumab monotherapy as first-line treatment for metastatic or unresectable, recurrent head and neck squamous cell carcinoma

Annals of Oncology ◽

10.1016/j.annonc.2020.08.1087 ◽

2020 ◽

Vol 31 ◽

pp. S683

Author(s):

K.J. Harrington ◽

W.N. William ◽

A. Khilnani ◽

A.P. Algazi

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Recurrent Head ◽

Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): First results of phase II trial GORTEC 2008-03.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.5567 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 5567-5567 ◽

Cited By ~ 8

Author(s):

J. Guigay ◽

J. Fayette ◽

A. Dillies ◽

C. Sire ◽

J. N. Kerger ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

First Results ◽

926TiP Phase II trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M SCCHN)

Annals of Oncology ◽

10.1016/j.annonc.2021.08.1336 ◽

2021 ◽

Vol 32 ◽

pp. S814

Author(s):

G. Obara ◽

J. Sun ◽

D. Loo ◽

C. Bohac

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

Neck Squamous Cell Carcinoma ◽

Line Treatment ◽

First Line ◽

Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)

Annals of Oncology ◽

10.1093/annonc/mdy040 ◽

2018 ◽

Vol 29 (4) ◽

pp. 1004-1009 ◽

Cited By ~ 13

Author(s):

M. Tahara ◽

N. Kiyota ◽

T. Yokota ◽

Y. Hasegawa ◽

K. Muro ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Combination Treatment ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽